Organoid Science announced that it has submitted a securities report to the Financial Services Commission and has entered into full-scale public offering procedures for listing on KOSDAQ.
The company is offering a total of 1.2 million shares, and the desired offering price band per share is set at 17,000 won to 21,000 won. Accordingly, the offering amount will amount to approximately 25.2 billion won based on the upper end of the offering price band. The funds raised will be used for the advancement of the company's technology, global business, and clinical development.
Organoid Science will conduct demand forecasting for institutional investors for five business days from March 7 to 13, and then accept general subscriptions from the 19th to the 20th. Korea Investment & Securities is the lead underwriter for the listing.
Organoid Science has established and standardized a step-by-step organoid production process and successfully commercialized it. Currently, the company is conducting advanced regenerative medicine clinical trials for the organoid regeneration treatment 'ATORM', and has been commercializing the organoid-based new material efficacy evaluation solution 'ODISEI' since 2020, continuing collaborations with domestic large corporations, large hospitals, and global pharmaceutical companies.
Yoo Jong-man, CEO of Organoid Science, said, “We will expand the company’s organoid technology to the global market and lead the future of regenerative medicine,” and “We will do our best to use this listing as an opportunity to make the organoid technology industry a new growth engine for the country.”
- See more related articles
You must be logged in to post a comment.